It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Diagnosis based on histopathology for skin cancer detection is today’s gold standard and relies on the presence or absence of biomarkers and cellular atypia. However it suffers drawbacks: it requires a strong expertise and is time-consuming. Moreover the notion of atypia or dysplasia of the visible cells used for diagnosis is very subjective, with poor inter-rater agreement reported in the literature. Lastly, histology requires a biopsy which is an invasive procedure and only captures a small sample of the lesion, which is insufficient in the context of large fields of cancerization. Here we demonstrate that the notion of cellular atypia can be objectively defined and quantified with a non-invasive in-vivo approach in three dimensions (3D). A Deep Learning (DL) algorithm is trained to segment keratinocyte (KC) nuclei from Line-field Confocal Optical Coherence Tomography (LC-OCT) 3D images. Based on these segmentations, a series of quantitative, reproducible and biologically relevant metrics is derived to describe KC nuclei individually. We show that, using those metrics, simple and more complex definitions of atypia can be derived to discriminate between healthy and pathological skins, achieving Area Under the ROC Curve (AUC) scores superior than 0.965, largely outperforming medical experts on the same task with an AUC of 0.766. All together, our approach and findings open the door to a precise quantitative monitoring of skin lesions and treatments, offering a promising non-invasive tool for clinical studies to demonstrate the effects of a treatment and for clinicians to assess the severity of a lesion and follow the evolution of pre-cancerous lesions over time.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 DAMAE Medical, Paris, France
2 University of Barcelona, Melanoma Unit, Hospital Clinic Barcelona, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); CIBER de enfermedades raras, Instituto de Salud Carlos III, Barcelona, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
3 University of Siena, Dermatology Unit - Department of Medical, Surgical and Neurological Sciences, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641)
4 Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Groupe d’Imagerie Cutanée Non Invasive (GICNI) of the Société Française de Dermatologie (SFD), Paris, France (GRID:grid.4989.c); Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium (GRID:grid.418119.4) (ISNI:0000 0001 0684 291X)
5 University of Siena, Dermatology Unit - Department of Medical, Surgical and Neurological Sciences, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641); Groupe d’Imagerie Cutanée Non Invasive (GICNI) of the Société Française de Dermatologie (SFD), Paris, France (GRID:grid.9024.f)
6 DAMAE Medical, Paris, France (GRID:grid.9024.f)
7 Groupe d’Imagerie Cutanée Non Invasive (GICNI) of the Société Française de Dermatologie (SFD), Paris, France (GRID:grid.9024.f); la Timone hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Department of Dermatology and skin cancer, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817)
8 Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
9 Laboratoire Charles Fabry, Université Paris-Saclay, Institut d’Optique Graduate School, Palaiseau, France (GRID:grid.462674.5) (ISNI:0000 0001 2265 1734)
10 University Hospital of Saint-Etienne, Department of Dermatology, Saint-Etienne, France (GRID:grid.412954.f) (ISNI:0000 0004 1765 1491)